Table 2.

Prognostic effects of different TLS characteristics on different disease types

TLS features		Disease types	Methodology	Prognostic value	Experimental Subject	References
Quantity and density	High TLS density	iCCA	mIHC	Positive	Patients	[16]
		HCC	IHC	Positive	Patients	[106]
	Quantity	Non-functional Pancreatic neuroendocrine tumours	H&E IHC	No prognostic significance	Patients	[16]
Locations	Intra-tumoral	iCCA	mIHC	Positive	Patients	[16]
		CRC liver metastases	mIHC	Positive	Patients	[104]
		HCC	H&E IHC	Positive	patients	[49]
	Peritumoral	iCCA	mIHC	Negative	Patients	[16]
		Melanoma	mIHC	Positive	Patients	[107]
		HCC	H&E IHC	No prognostic significance	patients	[49]
Molecular or tissue characteristics	CXCL13	Bladder cancer	RNA seq	Positive	Patients	[108]
		Influenza A virus	Flow cytometry	Positive	Mice	[109]
	IL-22, IL-23	Crohn’s disease	H&E, RNA seq, Flow cytometry	Positive	Mice	[110]
	HEV	BC	IHC	Positive	patients	[49]
	ND	Bladder cancer	IHC	Positive	patients	[111]
	CD153/CD30	Chronic kidney disease	Flow cytometry, RNA seq	Negative	Mice	[82]
		Endothelial notch signaling	RNA seq, Flow cytometry, IF	Negative	Mice	[112]

mIHC: Multiplex immunohistochemistry; IHC: Immunohistochemistry; H&E: Hematoxylin and eosin staining; RNA seq: RNA sequencing; IF: Immunofluorescence